Time to resolution of viremia [ Time Frame: Every 12 hr, from date of randomization until resolution of viremia or until fever subsides for 1 day, whichever came first. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Time to clearance of NS1 antigen [ Time Frame: Every 12 hr, from date of randomization until resolution of viremia or until fever subsides for 1 day, whichever came first. ] [ Designated as safety issue: No ]

Time of subsidence of fever [ Time Frame: From date of randomization until fever subsides ] [ Designated as safety issue: No ]

Patients with confirmed dengue infection who meet all inclusion and exclusion criteria will be enrolled in the study and admitted in the hospital. Patients will be randomly assigned in a pre-specified ratio of 1:1:1 to one of the following study groups: ivermectin 200-400 µg/kg single daily dose for 2 days, ivermectin 200-400 µg/kg single daily dose for 3 days, or placebo. Tablets of ivermectin or placebo will be administered for 3 days. Clinical exam will be performed daily during hospitalization and blood samples will be collected for hematology, clinical chemistry, serology, viral load and quantitative nonstructural 1 (NS1) antigen. Safety assessment will be conducted during admission. Patients will be discharged one day after fever subsidence and will be asked to return 2 weeks after first dose of study medication for safety assessment and blood sampling.

Eligibility

Ages Eligible for Study:

15 Years and older (Child, Adult, Senior)

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria:

Adults ages of 15 or greater.

History or presence of fever (temperature > 38°C) of ≤ 72 hr duration.

Clinical suspicion of dengue infection such as high fever without an evidence or suspected focus of infection on clinical examination.

Positive NS 1 strip assay

Exclusion Criteria:

Clinically significant abnormal laboratory results which are deemed to be unassociated with dengue infection

Clinical evidence or a history of significant respiratory, metabolic, renal, hepatic, hematologic or chronic diseases

History of autoimmune, immune dysfunction disorder or taking warfarin

Clinical suspicion of any bacterial infection

Pregnancy and lactating women

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02045069